〔Abstract〕 Objective To analyze the clinical effect of betaloc in the treatment of dilated cardiomyopathy (DCM). Methods A total of 98 DCM patients treated in Zhengzhou First People's Hospital from March 2019 to March 2020 were selected and divided into a control group and an observation group according to random number table method, with 49 cases in each group. The control group was given conventional treatment, and the observation group was given betaloc on the basis of conventional treatment. The cardiac function related indicators, heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), clinical efficacy and quality of life score were compared between the two groups after treatment. Results The left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) in the observation group were lower than those in the control group, and the left ventricular ejection fraction (LVEF) and cardiac index (CI) were higher than those in the control group, the differences were statistically significant (P < 0.05). HR, SBP and DBP in the observation group were lower than those in the control group after treatment, and the differences were statistically significant (P < 0.05). The total effective rate of the observation group was 93.88%, higher than 79.59% of the control group, and the difference was statistically significant (P < 0.05). The scores of quality of life scale in the observation group were higher than those in the control group, and the differences were statistically significant (P < 0.05). Conclusion In the clinical treatment of DCM, betaloc combined with conventional treatment can effectively improve the cardiac function of patients.